Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 1.00 |
| ▸ | FNTA | P49354 | 6/20 | 0.42 |
| ▸ | FNTB | P49356 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapitant SCHEMBL6437147 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL14071561 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL121135 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL7582571 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL13575759 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL30695498 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL7768046 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL8543936 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| SCHEMBL8543712 | 0.94 | TACR1 (0.89) | TACR1FNTAFNTBMEN1CYP3A4 | |
| SCHEMBL8956844 | 0.94 | TACR1 (0.89) | TACR1FNTAFNTBMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912174-B1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH NON-PEPTIDAL NEURIKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-04-28 | — | — | EP | claimed |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MERCK & CO., INC. | 2002-03-21 | — | — | US | claimed |
| EP-0912174-A4 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO INC (US) | 2000-12-06 | — | — | EP | claimed |
| JP-2000514455-A | — | — | 2000-10-31 | — | — | JP | claimed |
| EP-0912174-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002158-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO., INC. (US) | 1998-01-22 | — | — | WO | claimed |
| EP-0912174-B1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH NON-PEPTIDAL NEURIKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | disclosed |
| US-6573261-B2 | Administering a tachykinin receptor antagonist | MERCK & CO., INC. | 2003-06-03 | — | — | US | disclosed |
| US-6525073-B2 | For achieving circadian rhythm phase-shifting effect in mammal | MERCK & CO. INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020142942-A1 | Method for treating premenstrual or late luteal phase syndrome | MERCK & CO. INC. | 2002-10-03 | — | — | US | disclosed |
| US-20010029244-A1 | Method for treating or preventing psychosomatic and psychoimmunologic disorders | MERCK & CO., INC. | 2001-10-11 | — | — | US | disclosed |
| US-6232311-B1 | ADMINISTERING AN ORALLY ACTIVE, LONG ACTING, CENTRAL NERVOUS SYSTEM-PENETRANT TACHYKININ RECEPTOR PARTICULARLY NEUROKININ-1 RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-05-15 | — | — | US | disclosed |
| EP-0912174-A4 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO INC (US) | 2000-12-06 | — | — | EP | disclosed |
| US-6140324-A | ADMINISTERING TACHYKININ ANTAGONIST AND MUSCARINIC ANTAGONIST AND/OR ANTIHISTAMINE, SUCH THAT THEY GIVE EFFECTIVE RELIEF FROM MOTION SICKNESS | MERCK SHARP & DOHME LTD. (GB) | 2000-10-31 | — | — | US | disclosed |
| US-6121261-A | ADMINISTERING DOSAGE OF A CENTRAL NERVOUS SYTEM-PENETRATING SELECTIVE NEUROKININ-1 RECEPTOR ANTAGONIST TO PATIENT | MERCK & CO., INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5981526-A | SYNERGISTIC TREATMENT OR PREVENTION OF MIGRAINE | MERCK SHARP & DOHME LTD. (GB) | 1999-11-09 | — | — | US | disclosed |
| EP-0912174-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002158-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO., INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5484804-A | Perhydroisoindole derivatives as antagonists of substance P | RHONE-POULENC RORER S.A. (FR) | 1996-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010029244-A1 | Method for treating or preventing psychosomatic and psychoimmunologic disorders | NPSR1, TACR2, NTSR2 | TACR1 7/4885FNTA 3576/4885FNTB 3688/4885 |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MTNR1A, PROKR1, NTSR2 | TACR1 45/4885FNTA 4439/4885FNTB 4505/4885 |
| US-20020142942-A1 | Method for treating premenstrual or late luteal phase syndrome | GNRHR, KISS1R, NPSR1 | TACR1 33/4885FNTA 4723/4885FNTB 4851/4885 |
| US-20030215456-A1 | Method of treating cancer | TACR1, TACR2, KLK3 | TACR1 1/4885FNTA 2302/4885FNTB 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.